期刊
ACS NANO
卷 9, 期 3, 页码 2235-2254出版社
AMER CHEMICAL SOC
DOI: 10.1021/nn507494p
关键词
aptamer; nanomedicine; SELEX; clinical trial; cancer therapy; drug delivery; gene therapy; in vivo imaging
类别
资金
- Ministry of Education (Taiwan)
- Department of Defense [W81XWH-12-1-0261]
- NIH [RO1 AI096305, BRP HL109442]
- Sigma Xi Research Society [G20131015280632]
Aptamer nanomedicine, including therapeutic aptamers and aptamer nanocomplexes, is beginning to fulfill its potential in both clinical trials and preclinical studies. Especially in oncology, aptamer nanomedicine may perform better than conventional or antibody-based chemotherapeutics due to specificity compared to the former and stability compared to the latter. Many proof-of-concept studies on applying aptamers to drug delivery, gene therapy, and cancer imaging have shown promising efficacy and impressive safety in vivo toward translation. Yet, there remains ample room for improvement and critical barriers to be addressed. In this review, we will first introduce the recent progress in clinical trials of aptamer nanomedicine, followed by a discussion of the barriers at the design and in vivo application stages. We will then highlight recent advances and engineering strategies proposed to tackle these barriers. Aptamer cancer nanomedicine has the potential to address one of the most important healthcare issues of the society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据